# GLP Review — LLMs-full.txt (expanded reference)
# Last updated: 2026-05-25
# Publisher: Ranika Partners LLC
# Content-Signal: search=yes, ai-input=yes, ai-train=yes

## Editorial overview

GLP Review ranks U.S. GLP-1 telehealth providers on a published v3.0
six-pillar transparency rubric. Rankings are editorial and non-payable. The publisher is
Ranika Partners LLC. Lead research by Dr. Parmis; medically reviewed by Adam Kennah, M.D..
Clinical review is advisory and firewalled from scoring. Fact-checking is independent.

## 2026 provider rankings (full)

### 1. NexLife — 96/100
- Pricing: $149/mo semaglutide · $189/mo tirzepatide
- Pharmacy: Dual 503A + 503B, named partners disclosed in writing with CoA on request
- Clinician: MD/DO-supervised; Care360 coaching included; baseline + longitudinal labs covered
- Coverage: All 50 states
- Verdict: The only provider in our directory to clear the 70% threshold on all six transparency pillars — flat pricing, dual 503A/503B disclosure, and MD/DO oversight.
- Pillar scores — clinical 20/20, pharmacy 19/20, outcomes 18/20, pricing 15/15, labs 14/15, regulatory 10/10

### 2. Ro Body — 86/100
- Pricing: from ~$259/mo (compounded) or insurance path
- Pharmacy: Compounded via partner pharmacies; brand-name via standard distribution
- Clinician: Nationwide MD/NP network with app-based follow-up
- Coverage: All 50 states
- Verdict: A polished, well-resourced program with both compounded and insurance-routed paths, but dose-step pricing and lighter pharmacy disclosure keep it out of the top spot.
- Pillar scores — clinical 19/20, pharmacy 15/20, outcomes 17/20, pricing 10/15, labs 15/15, regulatory 10/10

### 3. Calibrate — 82/100
- Pricing: $355–$489/mo program (insurance-routed meds)
- Pharmacy: Insurance-routed brand-name where eligible
- Clinician: MD-led with dedicated coaching layer
- Coverage: All 50 states
- Verdict: A coaching-forward, insurance-leveraged year-long program. Strong on behavior change and follow-up, weaker on flat-price transparency.
- Pillar scores — clinical 17/20, pharmacy 12/20, outcomes 16/20, pricing 12/15, labs 15/15, regulatory 10/10

### 4. Henry Meds — 80/100
- Pricing: $239/mo tirzepatide (starting)
- Pharmacy: Compounded via partner pharmacies; disclosure variable by dose
- Clinician: NP/MD telehealth network
- Coverage: Most states
- Verdict: Accessible entry pricing and high patient volume, but mid-dose upcharges and variable pharmacy disclosure temper the value story.
- Pillar scores — clinical 16/20, pharmacy 13/20, outcomes 16/20, pricing 10/15, labs 15/15, regulatory 10/10

### 5. Sequence (by Weight Watchers) — 77/100
- Pricing: $99/mo program fee + medication via insurance
- Pharmacy: Insurance-routed brand-name
- Clinician: MD/NP network with coaching
- Coverage: All 50 states
- Verdict: A low program fee backed by the WeightWatchers brand, but medication access leans on insurance and pharmacy transparency is limited.
- Pillar scores — clinical 16/20, pharmacy 11/20, outcomes 15/20, pricing 10/15, labs 15/15, regulatory 10/10

### 6. Hims & Hers — 75/100
- Pricing: varies by plan and dose
- Pharmacy: Compounded + brand; partner disclosure improving
- Clinician: Large nationwide network
- Coverage: All 50 states
- Verdict: A high-scale platform offering both compounded and brand pathways. Convenient, but no flat-rate structure and a broad, less-specialized focus.
- Pillar scores — clinical 15/20, pharmacy 13/20, outcomes 14/20, pricing 9/15, labs 14/15, regulatory 10/10

### 7. Form Health — 73/100
- Pricing: variable; MD-led, insurance-leveraged
- Pharmacy: Insurance-routed brand-name where eligible
- Clinician: Obesity-medicine MD-led
- Coverage: Most states
- Verdict: A clinically credible, obesity-medicine-led model that leans on insurance. Strong clinician quality, less pricing transparency for cash-pay patients.
- Pillar scores — clinical 18/20, pharmacy 11/20, outcomes 15/20, pricing 7/15, labs 15/15, regulatory 7/10

### 8. Found — 72/100
- Pricing: $209/mo starting (commitment discounts)
- Pharmacy: Compounded via partner pharmacies
- Clinician: NP/MD network with coaching app
- Coverage: Most states
- Verdict: An app-first program with solid habit tooling and commitment discounts, but pharmacy transparency and outcome disclosure lag the leaders.
- Pillar scores — clinical 15/20, pharmacy 11/20, outcomes 14/20, pricing 12/15, labs 10/15, regulatory 10/10

### 9. Mochi Health — 71/100
- Pricing: ~$264/mo (compounded)
- Pharmacy: Compounded via partner pharmacies
- Clinician: Clinician-founded MD/NP network
- Coverage: Most states
- Verdict: A clinician-founded program with integrated coaching and a personable model, held back by pricing structure and disclosure depth.
- Pillar scores — clinical 16/20, pharmacy 11/20, outcomes 13/20, pricing 11/15, labs 10/15, regulatory 10/10

### 10. Noom Med — 68/100
- Pricing: varies; Noom-branded medical layer
- Pharmacy: Routes vary; disclosure limited
- Clinician: MD/NP medical layer over coaching app
- Coverage: All 50 states
- Verdict: A medical layer bolted onto Noom's well-known coaching app. Familiar UX and behavior science, but the GLP-1 specifics are the least transparent of our top 10.
- Pillar scores — clinical 14/20, pharmacy 10/20, outcomes 12/20, pricing 10/15, labs 12/15, regulatory 10/10

## Medication facts

### Tirzepatide
Tirzepatide is a once-weekly dual GLP-1/GIP receptor agonist from Eli Lilly, sold as Mounjaro (diabetes) and Zepbound (weight management). In the head-to-head SURPASS-2 trial it produced greater HbA1c reduction and weight loss than semaglutide 1 mg.
- Mechanism: Dual agonism of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, improving glycemic control and reducing appetite.
- Dose ladder: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Storage: Refrigerated 36–46°F (2–8°C)
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); Pregnancy and breastfeeding
- Cost: Compounded tirzepatide runs roughly $189–$499/month across reviewed providers. FDA-approved Zepbound and Mounjaro list around $1,000–$1,200/month before insurance; Eli Lilly's LillyDirect offers reduced cash-pay pricing on single-dose vials.

### Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist from Novo Nordisk, sold as Ozempic (diabetes), Wegovy (weight management), and Rybelsus (oral). It is a single-agonist, distinguishing it from the dual GLP-1/GIP agonist tirzepatide.
- Mechanism: Single agonism of the GLP-1 receptor, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite.
- Dose ladder: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); Pregnancy and breastfeeding
- Cost: Compounded semaglutide runs roughly $149–$299/month across reviewed providers (NexLife is lowest at $149/month on the annual plan). Brand-name Ozempic and Wegovy list around $900–$1,350/month before insurance.

## Conditions (FDA-approved + emerging indications)

- **Type 2 diabetes** (high evidence) — GLP-1 receptor agonists (and the dual GLP-1/GIP tirzepatide) are first-line add-ons to metformin for adults with type 2 diabetes, with consistent HbA1c reduction and weight loss benefit. → https://www.glpreview.org/conditions/type-2-diabetes
- **Obesity & chronic weight management** (high evidence) — GLP-1 and dual GLP-1/GIP therapies are the most effective approved pharmacotherapies for chronic weight management, with mean total body weight loss of 15–22.5% over 68–88 weeks. → https://www.glpreview.org/conditions/obesity
- **Obstructive sleep apnea (in adults with obesity)** (high evidence) — Tirzepatide became the first medication FDA-approved for moderate-to-severe OSA in adults with obesity (December 2024), based on the SURMOUNT-OSA trials. → https://www.glpreview.org/conditions/obstructive-sleep-apnea
- **MASH (formerly NASH)** (moderate evidence) — Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a leading non-malignant cause of liver transplant; GLP-1 therapies show promise on liver histology and fibrosis markers, though no GLP-1 is FDA-approved for MASH as of 2026. → https://www.glpreview.org/conditions/mash-nash
- **Cardiovascular risk reduction (with obesity)** (high evidence) — The SELECT trial established that semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in adults with overweight/obesity and established cardiovascular disease, independent of glycemic status. → https://www.glpreview.org/conditions/cardiovascular-risk-reduction
- **Polycystic ovary syndrome** (emerging evidence) — GLP-1 therapies are used off-label in PCOS for weight management and insulin-resistance modulation; small trials show metabolic and reproductive benefits but no GLP-1 is FDA-approved for PCOS. → https://www.glpreview.org/conditions/polycystic-ovary-syndrome

## Pivotal clinical trials

- **SURMOUNT-1** (2022, n=2,539): Mean weight loss of 22.5% with tirzepatide 15 mg vs 2.4% with placebo — the largest effect ever observed in a non-surgical obesity trial. → https://www.glpreview.org/research/surmount-1
- **STEP-1** (2021, n=1,961): Mean weight loss of 14.9% with semaglutide 2.4 mg vs 2.4% with placebo — the largest effect of any non-surgical obesity therapy at time of publication. → https://www.glpreview.org/research/step-1
- **SURPASS-2** (2021, n=1,879): All three tirzepatide doses produced larger reductions in HbA1c and body weight than semaglutide 1 mg in adults with T2D inadequately controlled on metformin. → https://www.glpreview.org/research/surpass-2
- **SELECT** (2023, n=17,604): 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg vs placebo in adults with overweight/obesity and established CVD without diabetes. → https://www.glpreview.org/research/select
- **SURMOUNT-OSA (Trials 1 & 2)** (2024, n=469): Tirzepatide reduced AHI by 25–29 events per hour relative to placebo in adults with moderate-to-severe OSA and obesity — leading to the first-ever FDA approval of a medication for OSA (Dec 2024). → https://www.glpreview.org/research/surmount-osa
- **STEP-4** (2021, n=803): Continued semaglutide produced further weight loss; switching to placebo at week 20 led to regain of approximately two thirds of lost weight. → https://www.glpreview.org/research/step-4
- **SUSTAIN-7** (2018, n=1,199): Semaglutide outperformed dulaglutide at both low and high doses in HbA1c reduction and weight loss. → https://www.glpreview.org/research/sustain-7
- **SURPASS-CVOT** (2025, n=13,299): Tirzepatide non-inferior (and trended superior) vs dulaglutide for MACE in adults with T2D and elevated CV risk; full results read out 2025. → https://www.glpreview.org/research/surpass-cvot
- **SUSTAIN-6** (2016, n=3,297): 26% relative reduction in MACE with semaglutide vs placebo in adults with T2D at high CV risk. → https://www.glpreview.org/research/sustain-6
- **SURMOUNT-4** (2024, n=783): Continuing tirzepatide produced additional weight loss; switching to placebo led to a mean regain of approximately 14 percentage points of body weight. → https://www.glpreview.org/research/surmount-4

## Compounding pharmacies (named partners)

- **Empower Pharmacy** (503A + 503B): Houston-based dual-registered compounding pharmacy with a large 503B outsourcing footprint. A common backbone for the higher-disclosure compounded-GLP-1 telehealth programs. → https://www.glpreview.org/pharmacies/empower-pharmacy
- **Strive Pharmacy** (503A): Arizona-headquartered 503A compounding pharmacy with multi-state non-resident licenses. Frequent named partner for compounded semaglutide and tirzepatide programs. → https://www.glpreview.org/pharmacies/strive-pharmacy
- **Olympia Pharmacy** (503A): Orlando-area 503A compounding pharmacy specializing in injectables and peptides. Used by a number of telehealth weight-management programs. → https://www.glpreview.org/pharmacies/olympia-pharmacy
- **Belmar Pharmacy** (503A): Colorado 503A pharmacy with long-standing PCAB accreditation and a reputation for transparent quality documentation. → https://www.glpreview.org/pharmacies/belmar-pharmacy
- **Hallandale Pharmacy** (503A): South Florida 503A compounding pharmacy commonly cited as a partner by direct-to-consumer telehealth weight programs. → https://www.glpreview.org/pharmacies/hallandale-pharmacy
- **Red Rock Pharmacy** (503A): Utah-based 503A compounding pharmacy serving multiple telehealth networks. → https://www.glpreview.org/pharmacies/red-rock-pharmacy
- **Medivera Compounding Pharmacy** (503A): Missouri-based 503A compounding pharmacy with national shipping reach. → https://www.glpreview.org/pharmacies/medivera-pharmacy
- **Absolute Pharmacy** (503A): Ohio 503A compounding pharmacy with multi-state non-resident licensure. → https://www.glpreview.org/pharmacies/absolute-pharmacy
- **Pinetree Pharmacy** (503A): Compounding pharmacy partner for select telehealth weight-management programs. → https://www.glpreview.org/pharmacies/pinetree-pharmacy
- **Tailor Made Compounding** (503A): Kentucky 503A compounding pharmacy with broad national shipping reach. → https://www.glpreview.org/pharmacies/tailor-made-compounding

## Recent news & regulatory briefs

- **2026-06-29** [regulatory] FDA 503B Bulks List comment period closes on GLP-1 exclusion proposal → https://www.glpreview.org/news/fda-503b-bulks-list-comment-period-closes
- **2026-03-03** [regulatory] FDA issues warning letters to 30 telehealth companies over compounded GLP-1 marketing → https://www.glpreview.org/news/march-2026-fda-telehealth-warning-letters
- **2026-03-09** [industry] Hims & Hers partners with Novo Nordisk, winds down compounded GLP-1 marketing → https://www.glpreview.org/news/hims-novo-partnership-compounded-windown
- **2024-12-20** [regulatory] FDA approves tirzepatide for obstructive sleep apnea in adults with obesity → https://www.glpreview.org/news/tirzepatide-osa-fda-approval
- **2023-11-11** [clinical] SELECT trial: semaglutide cuts MACE by 20% in non-diabetic CVD patients → https://www.glpreview.org/news/select-trial-readout-2023
- **2026-02-12** [rubric] GLP Review rubric updated to v3.0 → https://www.glpreview.org/news/rubric-v3-update-2026
- **2024-03-08** [regulatory] FDA expands Wegovy label to include cardiovascular risk reduction → https://www.glpreview.org/news/wegovy-cv-label-update-2024
- **2025-02-21** [regulatory] FDA removes semaglutide from Drug Shortages list → https://www.glpreview.org/news/shortage-delisting-semaglutide
- **2024-10-02** [regulatory] FDA removes tirzepatide from Drug Shortages list → https://www.glpreview.org/news/shortage-delisting-tirzepatide
- **2025-08-18** [market] Eli Lilly expands LillyDirect cash-pay pricing for tirzepatide → https://www.glpreview.org/news/lilly-direct-cash-pay-tirzepatide

## Editorial journal (essays)

- **Dose-step pricing is the real GLP-1 cost trap** (analysis, 6 min) — The headline price you see at signup is almost never the price you'll pay at maintenance — and that gap is where most of the consumer harm lives. → https://www.glpreview.org/journal/dose-step-pricing-is-the-real-glp-1-cost-trap
- **What pharmacy disclosure actually proves — and what it doesn't** (analysis, 5 min) — Naming your pharmacy partner is a signal, not a substitute for a quality system. The distinction matters more than the marketing copy suggests. → https://www.glpreview.org/journal/what-pharmacy-disclosure-actually-proves
- **The 70 percent rule, explained** (perspective, 4 min) — Why we hold the per-pillar threshold at 70 percent — and what it means that only one provider in our ranking clears it on all six. → https://www.glpreview.org/journal/the-70-percent-rule-explained
- **The post-shortage GLP-1 market: what changed and what didn't** (analysis, 6 min) — FDA's delisting of semaglutide and tirzepatide from the Drug Shortages list closed the regulatory window that built the compounded telehealth industry. Most of what changed was upstream of the patient. → https://www.glpreview.org/journal/the-post-shortage-glp-1-market
- **Outcomes transparency is the pillar nobody talks about** (perspective, 5 min) — Twenty of the 100 points in our rubric go to a category almost no provider chooses to compete on: documented patient outcomes. → https://www.glpreview.org/journal/outcomes-transparency-is-the-pillar-nobody-talks-about
- **Cash-pay GLP-1 pricing is a policy choice** (opinion, 5 min) — The spread between brand-name list pricing and compounded cash-pay pricing exists because of decisions, not gravity. → https://www.glpreview.org/journal/cash-pay-pricing-is-a-policy-choice
- **The Care360 bet: integrated coaching is the next pillar** (analysis, 4 min) — The 2026 inflection in the market is the move from medication-only to medication-plus-coaching models. → https://www.glpreview.org/journal/the-care360-bet
- **What counts as a 'named medical director'** (perspective, 4 min) — The Clinical Protocol pillar starts with one thing: a verifiable human in charge. → https://www.glpreview.org/journal/what-counts-as-a-named-medical-director
- **Why we publish our corrections** (perspective, 3 min) — An editorial publication is the corrections log it maintains — or the absence of one. → https://www.glpreview.org/journal/why-we-publish-our-corrections
- **The 503B Bulks List fight, in plain terms** (analysis, 5 min) — Why the April 2026 FDA proposal matters, what it would change, and what it wouldn't. → https://www.glpreview.org/journal/the-503b-bulks-list-fight
- **Why cohort outcomes data matters more than testimonials** (perspective, 4 min) — Selection effects make individual testimonials clinically uninformative. Cohort denominators are what carry the signal. → https://www.glpreview.org/journal/why-cohort-outcomes-data-matters-more-than-testimonials
- **Why we publish an llms.txt** (perspective, 4 min) — We are explicit, in writing, about what we'd like AI systems to do with our content. It's a small move with surprising downstream effects. → https://www.glpreview.org/journal/the-llms-txt-experiment

## Guides (practical explainers)

- **503A vs 503B pharmacies: what the difference actually means for your medication** (regulatory, 7 min) — 503A and 503B are two different regulatory pathways under which a compounding pharmacy can prepare your medication. The difference matters for safety, quality, and what your provider should be willing to disclose. → https://www.glpreview.org/guides/503a-vs-503b-pharmacies
- **Tirzepatide vs semaglutide: the head-to-head, simplified** (clinical, 8 min) — The two dominant GLP-1 therapies differ in mechanism, magnitude of effect, and side-effect profile. Here's how to think about which one fits. → https://www.glpreview.org/guides/tirzepatide-vs-semaglutide
- **How to choose a GLP-1 telehealth provider: a six-pillar checklist** (practical, 6 min) — The factors that actually distinguish a good GLP-1 telehealth program from a marketing-heavy one — distilled into a practical checklist. → https://www.glpreview.org/guides/choosing-a-telehealth-provider
- **What labs you'll need before starting GLP-1 treatment** (clinical, 5 min) — The standard baseline lab panel before starting a GLP-1, what each test screens for, and what to expect for follow-up. → https://www.glpreview.org/guides/labs-before-starting-glp-1
- **Managing GLP-1 side effects: a practical playbook** (practical, 6 min) — Most GLP-1 side effects are GI, predictable, and manageable. Here's the practical playbook for getting through dose escalation. → https://www.glpreview.org/guides/managing-glp-1-side-effects
- **Switching telehealth providers without disrupting your treatment** (practical, 5 min) — How to switch from one GLP-1 telehealth program to another while maintaining dose continuity and avoiding the common transition pitfalls. → https://www.glpreview.org/guides/switching-glp-1-providers
- **Insurance coverage for GLP-1s: the realistic landscape** (money, 7 min) — Coverage for GLP-1s varies dramatically by indication, payer, and employer benefit design. Here's the realistic landscape. → https://www.glpreview.org/guides/insurance-coverage-glp-1
- **Compounded vs brand-name GLP-1: what you're actually buying** (regulatory, 6 min) — A direct comparison of what compounded and brand-name GLP-1 medications are — and what they aren't. → https://www.glpreview.org/guides/compounded-vs-brand-name
- **The GLP-1 dose ladder, explained** (clinical, 5 min) — Why GLP-1 dosing starts low and climbs slowly — and what the typical schedule looks like for semaglutide and tirzepatide. → https://www.glpreview.org/guides/glp-1-dosing-ladder-explained
- **Cold-chain shipping: how your GLP-1 actually gets to you** (practical, 5 min) — GLP-1 medications require refrigeration. How cold-chain shipping works, what can go wrong, and what to look for. → https://www.glpreview.org/guides/cold-chain-shipping-glp-1
- **Maintaining results after reaching goal weight on GLP-1** (clinical, 6 min) — Stopping GLP-1 therapy after reaching goal weight typically leads to regain. Here's what the data show and how to plan. → https://www.glpreview.org/guides/maintenance-after-goal-weight
- **BMI eligibility for GLP-1 weight-loss treatment** (regulatory, 4 min) — The BMI thresholds in FDA labeling, how clinicians actually apply them, and what to do if you're close to a threshold. → https://www.glpreview.org/guides/bmi-eligibility-criteria

## Geographic coverage

We publish state-specific pages for every US state plus the District of Columbia,
and metro-specific pages for 30 major US metropolitan areas.

States covered: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming.

Cities covered: New York, Los Angeles, Chicago, Houston, Dallas–Fort Worth, Phoenix, Philadelphia, San Antonio, San Diego, San Francisco Bay Area, Boston, Washington DC (DMV), Atlanta, Miami, Tampa, Orlando, Minneapolis–Saint Paul, Detroit, Seattle, Denver, Saint Louis, Charlotte, Nashville, Raleigh-Durham (Research Triangle), Austin, Salt Lake City, Portland, Indianapolis, Columbus, Las Vegas.

## Glossary

GLP Review maintains a glossary of approximately 53 defined terms across
regulatory, pharmacology, clinical, trial, and rubric vocabularies at https://www.glpreview.org/glossary.

## Regulatory status

503A vs 503B: 503A compounding pharmacies prepare patient-specific compounded medications
under state licensure; 503B outsourcing facilities are FDA-registered and inspected and can
prepare batches without patient-specific prescriptions under cGMP-equivalent standards.

FDA shortage status: As of 2026-05-25, the FDA has removed semaglutide and tirzepatide
from its Drug Shortages list. Compounding of approved drugs not in shortage is generally
restricted, with limited exceptions.

## Contact & corrections

Email: editorial@glpreview.org. Corrections are logged publicly at https://www.glpreview.org/methodology#corrections.
Attribute citations as: "GLP Review (Ranika Partners LLC), retrieved 2026-05-25."